Larada Sciences Engages Maxim Group As Investment Banker And Corporate Finance Advisor

SALT LAKE CITY, UT--(Marketwired - August 13, 2014) - Larada Sciences, Inc., maker and global marketer of the patented AirAllé™ professional lice device, today announced the engagement of New York City-based Maxim Group LLC to serve as the Company's exclusive corporate finance advisor and investment banker.

Claire Roberts, Chief Executive Officer of Larada Sciences, stated, "We are very pleased to be teaming with Maxim and look forward to leveraging their notable experience in formulating and executing capital market strategies that will allow us to support our global expansion and business growth objectives. In addition to providing us with counsel on capital formation and structuring, we will also look to them for assistance with mergers and acquisitions and other matters of corporate finance that will lead to enhancing value for our shareholders."

About Maxim Group LLC

Maxim Group LLC is a leading full-service investment banking, securities and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed income and derivative sales & trading, equity research and prime brokerage services to a diverse range of corporate clients, institutional investors and high net worth individuals. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission and the Municipal Securities Rulemaking Board (MSRB), and is a member of the following: Financial Industry Regulatory Authority (FINRA), Securities Insurance Protection Corporation (SIPC), NASDAQ Stock Market and NYSE Arca, Inc. To learn more about Maxim Group, visit www.maximgrp.com.

About Larada Sciences, Inc.

Headquartered in Salt Lake City, Larada Sciences is a privately held medical-device company founded in 2006 to commercialize breakthrough technology that has been clinically proven to kill head lice and 99.2% of their eggs in children and adults in a one-hour treatment using carefully controlled, heated air. The FDA-cleared, patented medical device, marketed as AirAllé™, offers consumers worldwide with a truly effective, eco-friendly, non-toxic and reliable alternative to prescription drugs and/or the traditional protracted, multi-week self-treatment regimen of topical shampoos, pesticides and fastidious combing, few of which have AirAllé's highly differentiating ability to kill the lice eggs that may later hatch and continue the infestation. The Company has succeeded in building the world's largest lice removal network comprised of AirAllé affiliates, which operate independent lice treatment centers and mobile services. The Company has 150 treatment locations in 18 countries, and it plans to expand distribution by releasing its second-generation AirAllé device targeting the home healthcare consumer product market. For more information, please visit www.airalle.com.